Luspatercept's use in a patient with transfusion‐dependent beta‐thalassemia and intrathoracic extramedullary hematopoiesis (EMH)
<h3>Key Clinical Message</h3><p dir="ltr">This case report and literature review examine the use of a relatively novel agent in a transfusion‐dependent beta‐thalassemia patient with extramedullary hematopoiesis (EMH). It examines the benefits and risks associated with its...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | , |
| منشور في: |
2024
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1864513542624903168 |
|---|---|
| author | Mohammed Najdat Seijari (17563263) |
| author2 | Awni Alshurafa (15468195) Mohamed A. Yassin (8361183) |
| author2_role | author author |
| author_facet | Mohammed Najdat Seijari (17563263) Awni Alshurafa (15468195) Mohamed A. Yassin (8361183) |
| author_role | author |
| dc.creator.none.fl_str_mv | Mohammed Najdat Seijari (17563263) Awni Alshurafa (15468195) Mohamed A. Yassin (8361183) |
| dc.date.none.fl_str_mv | 2024-05-01T00:00:00Z |
| dc.identifier.none.fl_str_mv | 10.1002/ccr3.8795 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/Luspatercept_s_use_in_a_patient_with_transfusion_dependent_beta_thalassemia_and_intrathoracic_extramedullary_hematopoiesis_EMH_/29715497 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biomedical and clinical sciences Cardiovascular medicine and haematology Clinical sciences Pharmacology and pharmaceutical sciences extramedullary hematopoiesis luspatercept thalassemia transfusion-dependent thalassemia |
| dc.title.none.fl_str_mv | Luspatercept's use in a patient with transfusion‐dependent beta‐thalassemia and intrathoracic extramedullary hematopoiesis (EMH) |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <h3>Key Clinical Message</h3><p dir="ltr">This case report and literature review examine the use of a relatively novel agent in a transfusion‐dependent beta‐thalassemia patient with extramedullary hematopoiesis (EMH). It examines the benefits and risks associated with its use and reviews the available literature while highlighting the drug's results in our patient with a higher risk profile.</p><p dir="ltr">Beta thalassemia can be complicated by EMH, which causes different symptoms based on location and size. Luspatercept is a new agent approved for transfusion‐dependent thalassemia and Non‐transfusion‐dependent thalassemia (NTDT). Still, its use in patients with EMH was not well studied, and literature showed an increased risk of EMH expansion or development of new masses after its use. We discuss, in this case, the results of luspatercept treatment in a patient with transfusion‐dependent thalassemia who is considered high risk for its use due to the patient's specific characteristics (history of symptomatic intrathoracic EMH, previous splenectomy, refusal to use antithrombotic medications). While also highlighting the benefits of using luspatercept regarding decreasing the iron overload and improving hemoglobin levels and examining how it was used safely to manage a transfusion‐dependent thalassemia patient with an extramedullary hematopoiesis mass with no adverse events of note.</p><h2>Other Information</h2><p dir="ltr">Published in: Clinical Case Reports<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1002/ccr3.8795" target="_blank">https://dx.doi.org/10.1002/ccr3.8795</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_34d717697d13f7e78e68d357860bf2dc |
| identifier_str_mv | 10.1002/ccr3.8795 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/29715497 |
| publishDate | 2024 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Luspatercept's use in a patient with transfusion‐dependent beta‐thalassemia and intrathoracic extramedullary hematopoiesis (EMH)Mohammed Najdat Seijari (17563263)Awni Alshurafa (15468195)Mohamed A. Yassin (8361183)Biomedical and clinical sciencesCardiovascular medicine and haematologyClinical sciencesPharmacology and pharmaceutical sciencesextramedullary hematopoiesisluspaterceptthalassemiatransfusion-dependent thalassemia<h3>Key Clinical Message</h3><p dir="ltr">This case report and literature review examine the use of a relatively novel agent in a transfusion‐dependent beta‐thalassemia patient with extramedullary hematopoiesis (EMH). It examines the benefits and risks associated with its use and reviews the available literature while highlighting the drug's results in our patient with a higher risk profile.</p><p dir="ltr">Beta thalassemia can be complicated by EMH, which causes different symptoms based on location and size. Luspatercept is a new agent approved for transfusion‐dependent thalassemia and Non‐transfusion‐dependent thalassemia (NTDT). Still, its use in patients with EMH was not well studied, and literature showed an increased risk of EMH expansion or development of new masses after its use. We discuss, in this case, the results of luspatercept treatment in a patient with transfusion‐dependent thalassemia who is considered high risk for its use due to the patient's specific characteristics (history of symptomatic intrathoracic EMH, previous splenectomy, refusal to use antithrombotic medications). While also highlighting the benefits of using luspatercept regarding decreasing the iron overload and improving hemoglobin levels and examining how it was used safely to manage a transfusion‐dependent thalassemia patient with an extramedullary hematopoiesis mass with no adverse events of note.</p><h2>Other Information</h2><p dir="ltr">Published in: Clinical Case Reports<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1002/ccr3.8795" target="_blank">https://dx.doi.org/10.1002/ccr3.8795</a></p>2024-05-01T00:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1002/ccr3.8795https://figshare.com/articles/journal_contribution/Luspatercept_s_use_in_a_patient_with_transfusion_dependent_beta_thalassemia_and_intrathoracic_extramedullary_hematopoiesis_EMH_/29715497CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/297154972024-05-01T00:00:00Z |
| spellingShingle | Luspatercept's use in a patient with transfusion‐dependent beta‐thalassemia and intrathoracic extramedullary hematopoiesis (EMH) Mohammed Najdat Seijari (17563263) Biomedical and clinical sciences Cardiovascular medicine and haematology Clinical sciences Pharmacology and pharmaceutical sciences extramedullary hematopoiesis luspatercept thalassemia transfusion-dependent thalassemia |
| status_str | publishedVersion |
| title | Luspatercept's use in a patient with transfusion‐dependent beta‐thalassemia and intrathoracic extramedullary hematopoiesis (EMH) |
| title_full | Luspatercept's use in a patient with transfusion‐dependent beta‐thalassemia and intrathoracic extramedullary hematopoiesis (EMH) |
| title_fullStr | Luspatercept's use in a patient with transfusion‐dependent beta‐thalassemia and intrathoracic extramedullary hematopoiesis (EMH) |
| title_full_unstemmed | Luspatercept's use in a patient with transfusion‐dependent beta‐thalassemia and intrathoracic extramedullary hematopoiesis (EMH) |
| title_short | Luspatercept's use in a patient with transfusion‐dependent beta‐thalassemia and intrathoracic extramedullary hematopoiesis (EMH) |
| title_sort | Luspatercept's use in a patient with transfusion‐dependent beta‐thalassemia and intrathoracic extramedullary hematopoiesis (EMH) |
| topic | Biomedical and clinical sciences Cardiovascular medicine and haematology Clinical sciences Pharmacology and pharmaceutical sciences extramedullary hematopoiesis luspatercept thalassemia transfusion-dependent thalassemia |